{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T00:23:30Z","timestamp":1794615810690,"version":"4.9.1"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Cytomegalovirus (CMV) infection is an underrecognized complication in children with acute lymphoblastic leukemia (ALL). While CMV disease is well documented in transplant recipients, its clinical course in nontransplant settings remains poorly defined. Disseminated ganciclovir-resistant CMV infection is a rare complication in nontransplant children with ALL, and its optimal management remains uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Observations:<\/jats:title>\n                    <jats:p>We describe an 8-year-old patient with T-ALL receiving maintenance chemotherapy who developed high levels of CMV viremia without initial end-organ disease and subsequent emergence of ganciclovir-resistant CMV infection. Despite prolonged valganciclovir therapy and the subsequent use of foscarnet and maribavir, the patient developed CMV-related complications, including CMV retinitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This case underscores the potential severity of CMV in nontransplant pediatric ALL with prolonged lymphopenia, challenges of antiviral resistance, and limited treatment options for central nervous system involvement. The progression from asymptomatic viremia to clinically significant CMV disease remains poorly understood. Enhanced CMV surveillance protocols and resistance-guided treatment strategies may be warranted in selected high-risk populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mph.0000000000003263","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:02:11Z","timestamp":1786644131000},"page":"e285-e288","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Disseminated Ganciclovir-Resistant Cytomegalovirus in a Nontransplant Pediatric ALL Patient: A Case Report"],"prefix":"10.1097","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8250-6815","authenticated-orcid":false,"given":"Marielys","family":"Collazo-Roman","sequence":"first","affiliation":[{"name":"Pediatrics, Pediatric Infectious Diseases"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi","family":"O\u2019Connor","sequence":"additional","affiliation":[{"name":"Pediatrics, Hematology, and Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William S.","family":"Wilson","sequence":"additional","affiliation":[{"name":"Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Smitherman","sequence":"additional","affiliation":[{"name":"Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Belhorn","sequence":"additional","affiliation":[{"name":"Pediatrics, Pediatric Infectious Diseases"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Willis","sequence":"additional","affiliation":[{"name":"Pediatrics, Pediatric Infectious Diseases"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"R1-20260928","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5500\/wjt.v5.i4.287","article-title":"Cytomegalovirus infection in the bone marrow transplant patient","volume":"5","author":"Bhat","year":"2015","journal-title":"World J Transplant"},{"key":"R2-20260928","first-page":"239","article-title":"Cytomegalovirus disease in children with acute lymphoblastic leukemia: a case series study","volume":"9","author":"\u00c7a\u011flar","year":"2019","journal-title":"J Behcet Uz Child Hosp"},{"key":"R3-20260928","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12985-020-01302-4","article-title":"Co-infections of human herpesviruses (CMV, HHV-6, HHV-7 and EBV) in non-transplant acute leukemia patients undergoing chemotherapy","volume":"17","author":"Handous","year":"2020","journal-title":"Virol J"},{"key":"R4-20260928","doi-asserted-by":"crossref","first-page":"ofac686","DOI":"10.1093\/ofid\/ofac686","article-title":"Maribavir for cytomegalovirus treatment in the real world\u2014not a silver bullet","volume":"10","author":"Fung","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"R5-20260928","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/infdis\/jiaa462","article-title":"Drug resistance mutations and associated phenotypes detected in clinical trials of maribavir for treatment of cytomegalovirus infection","volume":"226","author":"Chou","year":"2022","journal-title":"J Infect Dis"},{"key":"R6-20260928","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/S1473-3099(19)30107-0","article-title":"Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Ljungman","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"R7-20260928","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40506-021-00253-w","article-title":"CMV infection in hematopoietic stem cell transplantation: prevention and treatment strategies","volume":"13","author":"Jakharia","year":"2021","journal-title":"Curr Treat Options Infect Dis"},{"key":"R8-20260928","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/infdis\/jiz454","article-title":"Cytomegalovirus infection in solid organ and hematopoietic cell transplantation: state of the evidence","volume":"221","author":"Haidar","year":"2021","journal-title":"J Infect Dis"},{"key":"R9-20260928","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1182\/blood-2016-06-688432","article-title":"How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients","volume":"128","author":"El Chaer","year":"2016","journal-title":"Blood"},{"key":"R10-20260928","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/cid\/ciad709","article-title":"Treatment for first cytomegalovirus infection post\u2013hematopoietic cell transplant in the AURORA trial: a multicenter, double-blind, randomized, phase 3 trial comparing maribavir with valganciclovir","volume":"78","author":"Papanicolaou","year":"2024","journal-title":"Clin Infect Dis"},{"key":"R11-20260928","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.ajt.2025.10.018","article-title":"Determinants of virological outcomes in kidney transplant recipients treated with maribavir for refractory cytomegalovirus infection","volume":"26","author":"Kasriel","year":"2026","journal-title":"Am J Transplant"},{"key":"R12-20260928","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/INF.0000000000001595","article-title":"Valganciclovir dosing for cytomegalovirus prophylaxis in pediatric solid-organ transplant recipients: a prospective pharmacokinetic study","volume":"36","author":"Peled","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"R13-20260928","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1093\/jpids\/piad059","article-title":"Current and emerging antiviral agents in the prevention and treatment of cytomegalovirus in pediatric transplant recipients","volume":"13","author":"Valencia Deray","year":"2024","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R14-20260928","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/FTD.0000000000001050","article-title":"Subtherapeutic exposure of ganciclovir in children despite appropriate dosing: a short communication","volume":"45","author":"Marfil","year":"2023","journal-title":"Ther Drug Monit"},{"key":"R15-20260928","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/infdis\/jit475","article-title":"High rate of cytomegalovirus drug resistance among patients receiving preemptive antiviral treatment after haploidentical stem cell transplantation","volume":"209","author":"Shmueli","year":"2014","journal-title":"J Infect Dis"},{"key":"R16-20260928","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/cid\/cix259","article-title":"Risk factors and outcomes of ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients","volume":"65","author":"Fisher","year":"2017","journal-title":"Clin Infect Dis"},{"key":"R17-20260928","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/jac\/dkae094","article-title":"Absence of maribavir penetration into the central nervous system: confirmation by multiple cerebrospinal fluid dosages in a solid organ transplant recipient","volume":"79","author":"Luque-Paz","year":"2024","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MPH.0000000000003263","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:00:23Z","timestamp":1790622023000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MPH.0000000000003263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000003263","relation":{},"ISSN":["1077-4114","1536-3678"],"issn-type":[{"value":"1077-4114","type":"print"},{"value":"1536-3678","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"assertion":[{"value":"2026-01-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}